Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
phase 3
Biotech
Immunome's desmoid tumor treatment triumphs in phase 3
The therapy cut the risk of disease progression or death by 84% for patients with desmoid tumors, data one analyst calls a “near best-case outcome.”
Gabrielle Masson
Dec 15, 2025 10:42am
Arcus halts Gilead-partnered TIGIT trials as it reworks R&D
Dec 12, 2025 10:00am
Capricor sets up 2nd DMD approval attempt with ph. 3 win
Dec 3, 2025 11:11am
Novartis’ phase 3 wins in Sjögren's see high placebo effect
Oct 29, 2025 12:03pm
BridgeBio's calcium deficiency candidate scores phase 3 win
Oct 29, 2025 7:00am
Neuphoria nixes social anxiety program after phase 3 flop
Oct 21, 2025 10:44am
